Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from ConvaTec ( (GB:CTEC) ).
Convatec Group PLC announced that its Interim Chief Executive Officer, Jonny Mason, and Interim Chief Financial Officer, Fiona Ryder, have both purchased significant shares in the company. Mason acquired 50,000 shares at an average price of 234.81 pence, while Ryder purchased 21,263 shares at 233.96 pence. These transactions, conducted on the London Stock Exchange, reflect a potential vote of confidence in the company’s future prospects by its top executives.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £315.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.
ConvaTec’s strong financial performance and strategic positioning are tempered by bearish technical indicators and a high valuation. Regulatory challenges may pose risks, but the company’s innovation pipeline and operational strength support a moderately positive outlook.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec is a global medical products and technologies company specializing in solutions for the management of chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, with operations in around 90 countries and revenues exceeding $2 billion in 2024. The company is a member of the FTSE 100 Index.
Average Trading Volume: 8,029,274
Technical Sentiment Signal: Hold
Current Market Cap: £4.76B
Find detailed analytics on CTEC stock on TipRanks’ Stock Analysis page.